Magnus Medical raises $64M Series B for rapid-acting depression neurostimulation
Summary
Magnus Medical raised $64 million in Series B funding led by JAZZ Venture Partners and Red Tree Venture Capital, with participation from Maj Invest, Dolby Family Ventures, and Still Capital Partners. The Burlingame, California-based company is commercializing the SAINT individualized, non-invasive neurostimulation technology licensed from Stanford University. Clinical trials published in the American Journal of Psychiatry showed 79% of treatment-resistant depression patients entering remission after five days of treatment.
Why it matters
Magnus Medical's SAINT protocol represents a paradigm shift in psychiatric treatment by using advanced imaging to precisely target neurostimulation to each patient's unique brain connectivity pattern. With FDA Breakthrough Device Designation and peer-reviewed evidence of rapid, high remission rates in treatment-resistant depression, the funding accelerates commercialization of what could become the first precision neuromodulation therapy for major depressive disorder in emergency and clinical settings.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial